A Randomized, Double-Blind, Placebo-Controlled, Clinical Evaluation of the Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus
Phase of Trial: Phase III
Latest Information Update: 22 Jul 2019
Price : $35 *
At a glance
- Drugs Neramexane (Primary)
- Indications Tinnitus
- Focus Registrational; Therapeutic Use
- Acronyms EASE
- Sponsors Merz Pharmaceuticals GmbH
- 21 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 10 Jun 2014 New trial record
- 25 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.